

## MINTZ LEVIN

Ingrid A. Beattie, Ph.D., J.D. | 617 348 1838 | iabeattie@mintz.com

DEC 20 2007

One Financial Center  
Boston, MA 02111  
617-542-6000  
617-542-2241 fax  
www.mintz.com

## fax transmittal

## FROM:

Name Ingrid A. Beattie, Ph.D., J.D.

Date December 20, 2007

# of Pages 6

## To:

Name	Company	Business#	Fax #
Examiner Aaron Kosar	USPTO	571-270-3054	571-273-8300

## Comments:

Applicants: Farmer, et al.  
Serial Number: 09/424,527  
Filing Date: May 29, 2003  
For: PROBIOTIC LACTIC ACID BACTERIUM TO TREAT BACTERIAL INFECTIONS ASSOCIATED WITH SIDS

Examiner: Kosar, Aaron J.  
Art Unit: 1609

Please call us at 617-542-6000 if you experience any problems.

## STATEMENT OF CONFIDENTIALITY

The information contained in this fax is intended for the exclusive use of the addressee and may contain confidential or privileged information. If you are not the intended recipient, you are hereby notified that any form or dissemination of this communication is strictly prohibited. If this fax was sent in error, please immediately notify us by phone.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

BOSTON | WASHINGTON | NEW YORK | STAMFORD | LOS ANGELES | PALO ALTO | SAN DIEGO | LONDON

USPTO

12/19/2007 4:45:16 PM PAGE 1/008 Fax Server

TO: Ingrid Beattie COMPANY: Mintz Levin

RECEIVED  
CENTRAL FAX CENTER

DEC 20 2007

UNITED STATES PATENT AND  
TRADEMARK OFFICE

## Facsimile Transmission

To:	Name:	Ingrid Beattie
	Company:	Mintz Levin
	Fax Number:	617-542-2241
	Voice Phone:	617-348-1838
From:	Name:	Aaron Kosar
	Voice Phone:	571-270-3054

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

## Fax Notes:

Please find the enclosed Proposed Examiner's Amendment which, after consultation with my supervisor, would likely place the claims in condition for allowance, subject to your acceptance of the amendment.

Please contact me by COB, December 21, 2007, with your response. I can be reached at (571) 270-3054, generally Monday-Friday 7:30AM-5:00 PM EST.

Aaron Kosar

Date and time of transmission: Wednesday, December 19, 2007 4:45:00 PM  
Number of pages including this cover sheet: 06

USPTO

12/19/2007 4:45:18 PM PAGE 2/006 Fax Server

TO: Ingrid Beattie COMPANY: Mintz Levin

RECEIVED  
CENTRAL FAX CENTER

DEC 20 2007

Application/Control Number:

Page 2

09/424,527

Art Unit: 1651

**EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with

\*\*\* on \*\*\*.

The application has been amended as follows:

The Specification has been amended as follows:

The phrase "lactid acid bacterium" (page 19, ¶3, line 11) has been amended to correct a typographical error. The phrase has been amended to recite "lactic acid bacterium".

Claims:

1. A method reducing a bacterial gastrointestinal infection in a human, said bacterial gastrointestinal infection selected from the group consisting of, *Clostridium perfringens*, *Clostridium difficile*, *Clostridium botulinum*, *Clostridium trihurycum*, *Clostridium sporogenes*, *Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus*, comprising the steps of:

- a) orally administering to a human subject a composition comprising:
  - i.) viable colony forming units (CFU) of a non-pathogenic lactic acid bacteria, wherein said non-pathogenic lactic acid bacteria is *Bacillus coagulans*; and
  - ii) an oral electrolyte maintenance formulation; and
- b) allowing said non-pathogenic lactic acid bacteria to grow in the human subject's gastrointestinal tract, thereby reducing a bacterial gastrointestinal infection.